Drugs facing NCE-1 in 2029
1. Gomekli patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11084780 | SPRINGWORKS | Door construction |
Feb, 2041
(15 years from now) | |
| US11066358 | SPRINGWORKS | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Feb, 2041
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12090128 | SPRINGWORKS | Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof |
Feb, 2041
(15 years from now) | |
| US12295925 | SPRINGWORKS | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
Feb, 2041
(15 years from now) | |
| US11819487 | SPRINGWORKS | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
Feb, 2041
(15 years from now) | |
| US11806321 | SPRINGWORKS | Non-linear dosing of mirdametinib |
Feb, 2041
(15 years from now) | |
| US11453641 | SPRINGWORKS | Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
Feb, 2041
(15 years from now) | |
| US12275688 | SPRINGWORKS | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Feb, 2041
(15 years from now) | |
| US12263146 | SPRINGWORKS | Non-linear dosing of mirdametinib |
Feb, 2041
(15 years from now) | |
| US12037306 | SPRINGWORKS | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
Feb, 2041
(15 years from now) | |
| US12011424 | SPRINGWORKS | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
Feb, 2041
(15 years from now) | |
| US11571402 | SPRINGWORKS | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Feb, 2041
(15 years from now) | |
| US11883375 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US11839595 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US12257215 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US12220390 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US11806322 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US12029711 | SPRINGWORKS | Dosage forms of mirdametinib |
Mar, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 11, 2030 |
| Orphan Drug Exclusivity(ODE-488) | Feb 11, 2032 |
Drugs and Companies using MIRDAMETINIB ingredient
NCE-1 date: 11 February, 2029
Market Authorisation Date: 11 February, 2025
Treatment: Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic plexiform neurofibromas (pn) not amenable to complete resection
Dosage: TABLET, FOR SUSPENSION; CAPSULE
More Information on Dosage
GOMEKLI family patents
2. Grafapex patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7199162 | MEDEXUS | Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
Mar, 2026
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2030 |
| Orphan Drug Exclusivity(ODE-513) | Jan 21, 2032 |
| Orphan Drug Exclusivity(ODE-514) | Jan 21, 2032 |
Drugs and Companies using TREOSULFAN ingredient
NCE-1 date: 21 January, 2029
Market Authorisation Date: 21 January, 2025
Treatment: Administering treosulfan as a preparative regimen for allogeneic stem cell transplantation
Dosage: POWDER
More Information on Dosage
GRAFAPEX family patents
3. Journavx patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11834441 | VERTEX PHARMS INC | Substituted tetrahydrofurans as modulators of sodium channels |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 30, 2030 |
Drugs and Companies using SUZETRIGINE ingredient
NCE-1 date: 30 January, 2029
Market Authorisation Date: 30 January, 2025
Treatment: Treatment of moderate to severe acute pain in adults using suzetrigine
Dosage: TABLET
More Information on Dosage
JOURNAVX family patents
4. Qfitlia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9376680 | GENZYME CORP | Serpinc1 iRNA compositions and methods of use thereof |
Mar, 2033
(7 years from now) | |
| US9127274 | GENZYME CORP | Serpinc1 iRNA compositions and methods of use thereof |
Mar, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11091759 | GENZYME CORP | Methods and compositions for treating a Serpinc1-associated disorder |
Dec, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 28, 2030 |
| Orphan Drug Exclusivity(ODE-510) | Mar 28, 2032 |
| Orphan Drug Exclusivity(ODE-511) | Mar 28, 2032 |
Drugs and Companies using FITUSIRAN SODIUM ingredient
NCE-1 date: 28 March, 2029
Market Authorisation Date: 28 March, 2025
Treatment: Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia a or b with or without factor viii or ix inhibitors
Dosage: SOLUTION
More Information on Dosage
QFITLIA family patents
5. Romvimza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9181223 | DECIPHERA PHARMS | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
Mar, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12285430 | DECIPHERA PHARMS | Methods of treating disorders using CSF1R inhibitors |
Dec, 2039
(14 years from now) | |
| US11103507 | DECIPHERA PHARMS | Methods of treating disorders using CSF1R inhibitors |
Feb, 2040
(14 years from now) | |
| US11679110 | DECIPHERA PHARMS | Methods of treating disorders using CSF1R inhibitors |
Feb, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2030 |
Drugs and Companies using VIMSELTINIB ingredient
NCE-1 date: 14 February, 2029
Market Authorisation Date: 14 February, 2025
Treatment: Treatment of tenosynovial giant cell tumor
Dosage: CAPSULE
More Information on Dosage
ROMVIMZA family patents
6. Vanrafia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623819 | NOVARTIS | Therapy for complications of diabetes |
Aug, 2028
(3 years from now) | |
| US11874283 | NOVARTIS | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
Feb, 2032
(6 years from now) | |
| US9364458 | NOVARTIS | Stabilized pharmaceutical dosage forms comprising atrasentan |
Jul, 2034
(9 years from now) | |
| US10016393 | NOVARTIS | Stabilized pharmaceutical dosage forms comprising atrasentan |
Jul, 2034
(9 years from now) | |
| US11491137 | NOVARTIS | Methods of improving renal function |
Dec, 2040
(15 years from now) | |
| US11998526 | NOVARTIS | Methods of improving renal function |
Dec, 2040
(15 years from now) | |
| US12121509 | NOVARTIS | Methods of improving renal function |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2030 |
Drugs and Companies using ATRASENTAN HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2029
Market Authorisation Date: 02 April, 2025
Treatment: Treatment of primary immunoglobulin a nephropathy (igan)
Dosage: TABLET
More Information on Dosage
VANRAFIA family patents